Literature DB >> 20801686

Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination.

Wael E A Saad1, Wael M Darwish, Mark G Davies, David L Waldman.   

Abstract

PURPOSE: To compare functional and anatomic outcomes of transjugular intrahepatic portosystemic shunts (TIPSs) created with the specialized Viatorr stent versus a Wallstent/Fluency stent combination.
MATERIALS AND METHODS: Retrospective review of patients who underwent TIPS creation with stent-grafts was conducted over a 54-month period ending in June 2008. Patients were divided into three groups: Viatorr only, Fluency only, and combined Viatorr/Fluency, the latter of which was included in the overall evaluation but excluded from the comparative analysis between the Viatorr and Fluency groups. Patient demographics, Child-Pugh scores, and portosystemic gradient (PSG) reduction were compared. Patencies were calculated using the Kaplan-Meier method and compared.
RESULTS: A total of 126 TIPSs created with stent-grafts were found: 28 with Fluency stents, 93 with Viatorr devices, and five combined. No significance in demographic factors or PSGs was found among groups (P > .05). Major encephalopathy rates were 3.6% and 4.3% in the Fluency and Viatorr groups, respectively (P = 1.000). Hemodynamic success rates were 93% and 98% in the Fluency and Viatorr groups, respectively (P = .099). The primary unassisted patency rates at 6, 9, and 12 months were 87%, 81%, and 81%, respectively, in the Fluency group and 95%, 93%, and 89%, respectively, in the Viatorr group (P = .03). Portal and hepatic end stenoses were the causes of TIPS narrowing in the Fluency and Viatorr groups, respectively.
CONCLUSIONS: The Wallstent/Fluency stent combination is associated with a 1-year patency rate greater than 80%, with no significant difference versus the Viatorr stent regarding technical and hemodynamic success and encephalopathy rate. However, the Viatorr stent is associated with improved patency (89%) versus this bare stent/stent-graft combination.
Copyright © 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20801686     DOI: 10.1016/j.jvir.2010.06.009

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  16 in total

1.  Transjugular Intrahepatic Portosystemic Shunt (TIPS) versus Balloon-occluded Retrograde Transvenous Obliteration (BRTO) for the Management of Gastric Varices.

Authors:  Wael E A Saad; Michael D Darcy
Journal:  Semin Intervent Radiol       Date:  2011-09       Impact factor: 1.513

Review 2.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Effect of underdilated transjugular intrahepatic portosystemic shunt on prognosis in patients with prior splenectomy: a propensity score-matched case-control study.

Authors:  Wei Yao; Jia-Cheng Liu; Yong-Juan Wu; Chong-Tu Yang; Shu-Guang Ju; Ying-Liang Wang; Chao-Yang Wang; Song-Jiang Huang; Yao-Wei Bai; Yang Chen; Tong-Qiang Li; Chen Zhou; Bin Xiong
Journal:  Abdom Radiol (NY)       Date:  2022-07-12

4.  Elective Transjugular Intrahepatic Portosystemic Shunt Using Viatorr Stent-Grafts: A Single-Center Experience from China.

Authors:  Yu-Hua Li; Yue-Meng Wan; Hua-Mei Wu; Song-Quan Huang
Journal:  J Belg Soc Radiol       Date:  2022-06-29       Impact factor: 1.912

5.  Comparison of transjugular intrahepatic portosystemic shunt (TIPS) alone and combined with embolisation for the management of cardiofundal varices: a retrospective study.

Authors:  Jiaze Yu; Xiaoze Wang; Mingshan Jiang; Huaiyuan Ma; Zilin Zhou; Li Yang; Xiao Li
Journal:  Eur Radiol       Date:  2018-07-23       Impact factor: 5.315

Review 6.  The history and future of transjugular intrahepatic portosystemic shunt: food for thought.

Authors:  Wael E Saad
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

7.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

8.  Construction of Transjugular Intrahepatic Portosystemic Shunt: Bare Metal Stent/Stent-graft Combination versus Single Stent-graft, a Prospective Randomized Controlled Study with Long-term Patency and Clinical Analysis.

Authors:  Chang-Ming Wang; Xuan Li; Jun Fu; Jing-Yuan Luan; Tian-Run Li; Jun Zhao; Guo-Xiang Dong
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

9.  Potential Benefits of Underdilation of 8-mm Covered Stent in Transjugular Intrahepatic Portosystemic Shunt Creation.

Authors:  Jiacheng Liu; Jinqiang Ma; Chen Zhou; Chongtu Yang; Songjiang Huang; Qin Shi; Bin Xiong
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

Review 10.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.